Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Pediatric Acute Lymphoblastic Leukemia
100%
Cytotoxic Chemotherapy
100%
Adult Acute Lymphoblastic Leukemia
100%
Gemtuzumab Ozogamicin
100%
CD20
50%
Adverse Events
50%
Conventional Chemotherapy
50%
Antileukemic Agents
50%
CD19
50%
Successful Treatment
50%
Cure Rate
50%
Improved Outcomes
50%
Novel Agents
50%
Place in Therapy
50%
Treatment Regimen
50%
Surface Antigen
50%
Antibody-drug Conjugate
50%
CD22
50%
Chemotherapy Agents
50%
Armamentarium
50%
Optimal Places
50%
Event Understanding
50%
Monoclonal Antibody Targeting
50%
Resistance Mechanism
50%
Allogeneic Stem Cell Transplant
50%
Targeting Cells
50%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
100%
Inotuzumab Ozogamicin
100%
Pediatrics
50%
Cytotoxic Chemotherapy
50%
CD20
25%
Monoclonal Antibody
25%
Chemotherapy
25%
Stem Cell Transplant
25%
Membrane Antigen
25%
Antibody-Drug Conjugate
25%
Chemotherapy Agent
25%
Antileukemic Agent
25%
Adverse Event
25%
Immunology and Microbiology
Inotuzumab Ozogamicin
100%
Monoclonal Antibody
50%
CD19
50%
CD22
50%
Membrane Antigen
50%
Stem Cell Transplant
50%
Antibody Drug Conjugate
50%
CD20
50%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Inotuzumab Ozogamicin
100%
Cytotoxic Chemotherapy
50%
Monoclonal Antibody
25%
Adverse Event
25%
Antileukemic Agent
25%
Chemotherapy Agent
25%
Antibody Drug Conjugate
25%
Membrane Antigen
25%
Chemotherapy Regimen
25%